Ocotillol enhanced the antitumor activity of doxorubicin via p53-dependent apoptosis

Evidence-based Complementary and Alternative Medicine

Volumn 2013, Issue , 2013, Pages

  Wang, Hongbo ^a   Yu, Pengfei ^a   Bai, Jing ^a   Zhang, Jianqiao ^a   Kong, Liang ^a   Zhang, Fangxi ^a,b   Du, Guangying ^a   Pei, Shiqian ^a   Zhang, Lixia ^c   Jiang, Yongtao ^a   Tian, Jingwei ^a   Fu, Fenghua ^a  

^a YANTAI UNIVERSITY   (China)

^b Luye Pharma Group Ltd   (China)

^c BINZHOU MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; DOXORUBICIN; OCOTILLOL; PIFITHRIN ALPHA; PROTEIN P53; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CHEMOSENSITIZATION; CONTROLLED STUDY; CYTOTOXICITY; DRUG POTENTIATION; FLOW CYTOMETRY; GENE TARGETING; HUMAN; HUMAN CELL; MALE; MOUSE; NEOPLASM; NITROBLUE TETRAZOLIUM TEST; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; TUMOR MODEL; TUMOR VOLUME; TUMOR XENOGRAFT; WEIGHT CHANGE; WESTERN BLOTTING; WILD TYPE;

EID: 84881498365     PISSN: 1741427X     EISSN: 17414288     Source Type: Journal    
DOI: 10.1155/2013/468537     Document Type: Article

References (29)

1. Jemal A., Bray F., Center M. M., Ferlay J., Ward E., Forman D., Global cancer statistics. CA Cancer Journal for Clinicians 2011 61 2 69 90 2-s2.0-79952232216 10.3322/caac.20107
2. Lal R., Enting D., Kristeleit H., Systemic treatment of non-small-cell lung cancer. European Journal of Cancer 2011 47 3, supplement S375 S377 2-s2.0-80053240056 10.1016/S0959-8049(11)70209-X
3. Beil D. R., Wein L. M., Sequencing surgery, radiotherapy and chemotherapy: insights from a mathematical analysis. Breast Cancer Research and Treatment 2002 74 3 279 286 2-s2.0-0035990978 10.1023/A:1016357311845 (Pubitemid 34848355)
4. Carvalho C., Santos R. X., Cardoso S., Correia S., Oliveira P. J., Santos M. S., Moreira P. I., Doxorubicin: the good, the bad and the ugly effect. Current Medicinal Chemistry 2009 16 25 3267 3285 2-s2.0-70450215499 10.2174/092986709788803312
5. Drummond D. C., Meyer O., Hong K., Kirpotin D. B., Papahadjopoulos D., Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. Pharmacological Reviews 1999 51 4 691 743 2-s2.0-0032758610
6. Scott J. M., Khakoo A., MacKey J. R., Haykowsky M. J., Douglas P. S., Jones L. W., Modulation of anthracycline-induced cardiotoxicity by aerobic exercise in breast cancer: current evidence and underlying mechanisms. Circulation 2011 124 5 642 650 2-s2.0-80051494089 10.1161/CIRCULATIONAHA.111. 021774
7. Minotti G., Menna P., Salvatorelli E., Cairo G., Gianni L., Anthracyclines: molecular advances and pharmacologie developments in antitumor activity and cardiotoxicity. Pharmacological Reviews 2004 56 2 185 229 2-s2.0-2642566088 10.1124/pr.56.2.6 (Pubitemid 38720829)
8. Marine J.-C., Pharmacological rescue of p53 in cancer therapy: widening the sensitive tumor spectrum by targeting MDMX. Cancer Cell 2010 18 5 399 400 2-s2.0-78249233238 10.1016/j.ccr.2010.10.026
9. Harris S. L., Levine A. J., The p53 pathway: positive and negative feedback loops. Oncogene 2005 24 17 2899 2908 2-s2.0-18344377030 10.1038/sj.onc.1208615 (Pubitemid 40638098)
10. Qian H., Yang Y., Wang X., Curcumin enhanced adriamycin-induced human liver-derived Hepatoma G2 cell death through activation of mitochondria-mediated apoptosis and autophagy. European Journal of Pharmaceutical Sciences 2011 43 3 125 131 2-s2.0-79956339335 10.1016/j.ejps.2011.04.002
11. Spina A., Sorvillo L., Di Maiolo F., Inorganic phosphate enhances sensitivity of human osteosarcoma U2OS cells to doxorubicin via a p53-dependent pathway. Journal of Cellular Physiology 2012 228 1 198 206
12. Yuan X.-W., Zhu X.-F., Huang X.-F., Sheng P.-Y., He A.-S., Yang Z.-B., Deng R., Feng G.-K., Liao W.-M., Interferon- α enhances sensitivity of human osteosarcoma U2OS cells to doxorubicin by p53-dependent apoptosis. Acta Pharmacologica Sinica 2007 28 11 1835 1841 2-s2.0-35649003143 10.1111/j.1745-7254.2007.00662.x (Pubitemid 350029330)
13. Schwartsmann G., Ratain M. J., Cragg G. M., Wong J. E., Saijo N., Parkinson D. R., Fujiwara Y., Pazdur R., Newman D. J., Dagher R., Di Leone L., Anticancer drug discovery and development throughout the world. Journal of Clinical Oncology 2002 20 18 47S 59S 2-s2.0-0037106275
14. Karmazyn M., Moey M., Gan X. T., Therapeutic potential of ginseng in the management of cardiovascular disorders. Drugs 2011 71 15 1989 2008 2-s2.0-80053953131 10.2165/11594300-000000000-00000
15. Qi L.-W., Wang C.-Z., Yuan C.-S., Ginsenosides from American ginseng: chemical and pharmacological diversity. Phytochemistry 2011 72 8 689 699 2-s2.0-79954627696 10.1016/j.phytochem.2011.02.012
16. Wang Z., Zheng Q., Liu K., Li G., Zheng R., Ginsenoside Rh2 enhances antitumour activity and decreases genotoxic effect of cyclophosphamide. Basic and Clinical Pharmacology and Toxicology 2006 98 4 411 415 2-s2.0-33645702638 10.1111/j.1742-7843.2006.pto-348.x
17. Wang H., Yu P., Gou H., Cardioprotective effects of 20(S)-ginsenoside Rh2 against doxorubicin-induced cardiotoxicity in vitro and in vivo. Evidence-Based Complementary and Alternative Medicine 2012 2012 8 506214 10.1155/2012/506214
18. Xie X., Eberding A., Madera C., Fazli L., Jia W., Goldenberg L., Gleave M., Guns E. S., Rh2 synergistically enhances paclitaxel or mitoxantrone in prostate cancer models. Journal of Urology 2006 175 5 1926 1931 2-s2.0-33646002630 10.1016/S0022-5347(05)00891-8
19. Kim S.-W., Kwon H.-Y., Chi D.-W., Shim J.-H., Park J.-D., Lee Y.-H., Pyo S., Rhee D.-K., Reversal of P-glycoprotein-mediated multidrug resistance by ginsenoside Rg3. Biochemical Pharmacology 2003 65 1 75 82 2-s2.0-0037212768 10.1016/S0006-2952(02)01446-6 (Pubitemid 35447841)
20. Wang H., Li H., Zuo M., Zhang Y., Liu H., Fang W., Chen X., Lx2-32c, a novel taxane and its antitumor activities in vitro and in vivo. Cancer Letters 2008 268 1 89 97 2-s2.0-48149092967 10.1016/j.canlet.2008.03.051
21. Wang H., Ma X., Ren S., Buolamwini J. K., Yan C., A small-molecule inhibitor of MDMX activates p53 and induces apoptosis. Molecular Cancer Therapeutics 2011 10 1 69 79 2-s2.0-78751533820 10.1158/1535-7163.MCT-10-0581
22. Lizard G., Deckert V., Dubrez L., Moisant M., Gambert P., Lagrost L., Induction of apoptosis in endothelial cells treated with cholesterol oxides. American Journal of Pathology 1996 148 5 1625 1638 2-s2.0-0029960080 (Pubitemid 26135902)
23. Komarov P. G., Komarova E. A., Kondratov R. V., Christov-Tselkov K., Coon J. S., Chernov M. V., Gudkov A. V., A chemical inhibitor of p53 that protects mice from the side effects of cancer therapy. Science 1999 285 5434 1733 1737 2-s2.0-0033543728 10.1126/science.285.5434.1733 (Pubitemid 29428873)
24. Rutkoski T. J., Raines R. T., Evasion of ribonuclease inhibitor as a determinant of ribonuclease cytotoxicity. Current Pharmaceutical Biotechnology 2008 9 3 185 199 2-s2.0-47749114193 10.2174/138920108784567344 (Pubitemid 352024695)
25. Appel J. M., Nielsen D., Zerahn B., Jensen B. V., Skagen K., Anthracycline-induced chronic cardiotoxicity and heart failure. Acta Oncologica 2007 46 5 576 580 2-s2.0-34250305000 10.1080/02841860601156165 (Pubitemid 46911916)
26. Ahmad A., Sakr W. A., Rahman K. M. W., Anticancer properties of indole compounds: mechanism of apoptosis induction and role in chemotherapy. Current Drug Targets 2010 11 6 652 666 2-s2.0-77953483368 10.2174/138945010791170923
27. Darzynkiewicz Z., Bruno S., Del Bino G., Gorczyca W., Hotz M. A., Lassota P., Traganos F., Features of apoptotic cells measured by flow cytometry. Cytometry 1992 13 8 795 808 2-s2.0-0026492817 10.1002/cyto.990130802
28. Levine A. J., Oren M., The first 30 years of p53: growing ever more complex. Nature Reviews Cancer 2009 9 10 749 758 2-s2.0-70349442548 10.1038/nrc2723
29. Brown C. J., Lain S., Verma C. S., Fersht A. R., Lane D. P., Awakening guardian angels: drugging the P53 pathway. Nature Reviews Cancer 2009 9 12 862 873 2-s2.0-70450270900 10.1038/nrc2763